Care burden associated with sternal wound surgical site infections after coronary artery bypass graft

Rhodri Saunders¹, Maximilian Blüher¹ and Julie Lankiewicz²

1. Coreva Scientific, Freiburg, Germany; 2. Cardinal Health Medical Affairs, Mansfield, MA USA

Background

- Surgical site infection following coronary artery bypass graft (CABG) is a costly complication occurring in 1.6-7.4% of CABG patients in the EU¹
- Most concerning are superficial and deep sternal wound infections (SWIs) as they increase patient length of hospital stay and readmissions²

Objective

Quantify the EU-wide care burden of SWIs following CABG procedures to estimate the economic benefits of further reductions in SWI rates

Methods

 National surveillance data and peer-reviewed European publications were searched for the following parameters:



- CABG procedures per year
- SWI rate
- Ratio of superficial to deep SWIs
- Length of hospital stay for CABG patients
- Additional length of stay due to SWIs



Cost per day of intensive care unit and general ward

- If no data were available for a country, proxy values were used based on known EU data
- A previously presented Markov model was adapted to estimate the yearly burden of SWIs after CABG procedures

Results

- From the EU-28, sufficient data were identified in Austria, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, and United Kingdom (72.8% of the EU28 population)
- Rates of CABG ranged from 17.86 (Spain) to 64.75 (Denmark) per 100,000 population, while 2.4% (Germany) to 10.4% (Netherlands) of CABG patients were affected by SWIs (Fig. 1)
- In these ten countries, SWIs following CABG added
 - €96.92 million per year
 - 15,172 ICU days and 79,522 general ward days
 - 3,392 readmissions






Fig. 1 SWI rates. DSWI: Deep sternal wound infection, SSWI: superficial sternal wound infection. For Portugal no data on DSWI rates was available.

Conclusion

- Superficial and deep SWIs after CABG procedures come at considerable cost to healthcare providers
- An SWI reduction of 1% at 30 days could substantially reduce bed occupancy and save costs





- A 1%-point reduction in the 30-day SWI rate would result in savings of €18.03 million and 24,684 bed days
- SWIs increase the average cost of CABG by €418 (UK) to €1,720 (Netherlands, Fig. 2), which meant a 5.6% (UK) to 20.1% (Portugal, Fig. 3) increase of mean costs per procedure
- Extrapolating from the ten countries to the EU-28 we estimated a SWI burden of €117.87million per year

Fig. 2 Burden of SWIs following CABG. (A) average cost; increase per procedure. (B) per capita; *black border:* countries with sufficient data available; *borderless:* results through extrapolations based on data of other countries

Discussion

- A German costing study, not used in our analysis, was available to validate the model.³ An SSI case costs €7,051–8,342 more than a control case. Our model, using costs and incidences reported in this paper, estimated an increase of €7,711
- A group in the USA reduced their DSWI to zero (over 30 months and 590 procedures) after implementation of a Six Sigma assessment, in which they updated 15 of 42 perioperative processes and saved USD 600,000 compared with previous practice⁴
 - Key implementations were: Use of disposable ECG leads & wires, antibiotic-coated sutures, silver-impregnated dressings
- Disposable ECG leads were shown to reduce SSIs by 18.8% at 30-days post CABG (reaching significance at 90-days post CABG)⁵
 - The presented model indicates a cost saving of €16.03 million if this 18.8% reduction could be achieved across the EU-28




Fig. 3 SWI burden contribution to average CABG procedure cost.

References

- European centre for disease prevention and control, Annual 1. Epidemiological Report 2018, Healthcare-associated infections: surgical site infections
- Jenks, P.J. et al. J Hosp Infect. 2014 Jan;86(1):24-33 2.
- 3. Findeisen, A. et al. Eur J Cardiothorac Surg. 2018 Aug; 55(3):494–500,
- Kles, CL et al. Dimens Crit Care Nurs. 2015 Sep Oct;34(5):265-72 4.
- 5. Lankiewicz, JD et al. Am J Infect Control. 2018 Aug;46(8):949-951

Poster number EP019



9th EORNA Congress 2019 May 16-19. 2019 The Hague, The Netherlands



Disclosure

RS is the owner and MB is an employee of Coreva Scientific, which received consultancy fees for this work, JL is an employee of Cardinal Health.

Research funded by **Cardinal Health**

Copyright © 2019